Regulation News
Financial regulation news from the SEC, FINRA, and government agencies. Track policy changes, enforcement actions, and compliance updates affecting markets.
California Antitrust Scrutiny Intensifies on Paramount-WBD Merger
34 California Democrats push AG Bonta to scrutinize Paramount's $111B Warner Bros. Discovery takeover for antitrust harm, citing job losses and consolidation risks.
USDA Tightens SNAP Stocking Rules: Retailers Must Offer 28 Staple Items by Fall 2026
USDA finalizes SNAP stocking rules effective fall 2026, mandating 28 staple food varieties, impacting small grocers and convenience stores.
Capital One Faces Class Action Over Cancellation of Earned Credit Card Rewards
Capital One is sued for canceling earned credit card rewards after account closures, even when cardholders were not in default, with over $10,000 in rewards at stake.
Live Nation's Ticketmaster Axes 350 Jobs Amid Antitrust Overhaul
Ticketmaster has laid off 350 employees, or 8% of its global workforce, as parent Live Nation restructures amid a pending antitrust ruling and a $371 million operating loss.
Oklo Gains NRC Approval for Aurora Design, but Commercial Hurdles Remain
Oklo Inc. received NRC approval for its Aurora powerhouse design, halving the review time. Yet, the company has no built plants or binding power deals, and faces significant hurdles.
GM Recalls 40,440 Brake Fluid Bottles Over Sediment Contamination
General Motors is recalling 40,440 bottles of ACDelco brake fluid due to sediment that could impair braking, a potential safety hazard.
POET Technologies Faces Class Action After Marvell Cancels Celestial AI Orders
POET Technologies is under a securities class action after Marvell canceled all Celestial AI purchase orders. Lead-plaintiff deadline is June 29. Stock at $9.385.
Tesla Recalls 218,868 Vehicles in US; European FSD Approval Stalls
Tesla recalls 218,868 US vehicles over rearview camera delay. Stock slips 0.8% as European FSD approval faces regulatory hurdles.
FINRA Probes Morgan Stanley's Budapest Analyst Program Over Licensing
FINRA is investigating Morgan Stanley's Budapest analyst program after a whistleblower alleged unlicensed work on US and European deals and client data mishandling.
Cellectar Biosciences Secures $140M, Pushes Iopofosine Toward FDA Filing
Cellectar Biosciences secured up to $140 million in new funding and reported strong Phase 2b results for iopofosine, fueling plans for a confirmatory trial and FDA filing in Waldenström macroglobulinemia.
POET Technologies Stock Surges on Securities Lawsuit Over Canceled Marvell Order
POET Technologies shares surged 30% after a securities class action was filed over disclosure of canceled Marvell purchase orders.